Correlation Between Purple Biotech and Lumos Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Purple Biotech and Lumos Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Purple Biotech and Lumos Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Purple Biotech and Lumos Pharma, you can compare the effects of market volatilities on Purple Biotech and Lumos Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Purple Biotech with a short position of Lumos Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Purple Biotech and Lumos Pharma.

Diversification Opportunities for Purple Biotech and Lumos Pharma

-0.66
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Purple and Lumos is -0.66. Overlapping area represents the amount of risk that can be diversified away by holding Purple Biotech and Lumos Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lumos Pharma and Purple Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Purple Biotech are associated (or correlated) with Lumos Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lumos Pharma has no effect on the direction of Purple Biotech i.e., Purple Biotech and Lumos Pharma go up and down completely randomly.

Pair Corralation between Purple Biotech and Lumos Pharma

Given the investment horizon of 90 days Purple Biotech is expected to under-perform the Lumos Pharma. In addition to that, Purple Biotech is 8.21 times more volatile than Lumos Pharma. It trades about -0.03 of its total potential returns per unit of risk. Lumos Pharma is currently generating about -0.16 per unit of volatility. If you would invest  445.00  in Lumos Pharma on August 28, 2024 and sell it today you would lose (15.00) from holding Lumos Pharma or give up 3.37% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Purple Biotech  vs.  Lumos Pharma

 Performance 
       Timeline  
Purple Biotech 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Purple Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Lumos Pharma 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Lumos Pharma are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak primary indicators, Lumos Pharma may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Purple Biotech and Lumos Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Purple Biotech and Lumos Pharma

The main advantage of trading using opposite Purple Biotech and Lumos Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Purple Biotech position performs unexpectedly, Lumos Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will offset losses from the drop in Lumos Pharma's long position.
The idea behind Purple Biotech and Lumos Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk